Description: CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.
Home Page: www.cgxinc.com
Tower A, Korea Bio Park
Seongnam-si,
463-400
South Korea
Phone:
82 3 1628 2700
Officers
| Name | Title |
|---|---|
| Willim Schmdit | Exec. Officer |
| Hui-Sung Lee | Exec. Officer |
| Jong-Ryu Choi | Exec. Officer |
| Doh-Young Lee | Exec. Officer |
| Dr. Joong-Myung Cho Ph.D. | Chairman, Founder, CEO & Pres |
| Dr. Seonggu Ro Ph.D. | Co-Founder, Chief Technology Officer, Exec. VP and Director |
| Dr. In Chul Chung | VP & CFO |
| Mr. Sang-Cheon Ahn | Exec. Managing Director and Director |
| Dr. Yong-Rae Hong | Exec. MD & Research Head of Institute for Drug Discovery |
| Cheol-Soon Lee | Exec. Officer |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 9.3518 |
| IPO Date: | 2006-01-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |